Good morning, and welcome to Sun Life Financial Q2 2025 Conference Call. My name is Gaylene, and I will be your conference operator today. The conference is being recorded. The host of the call today is Natalie Brady, Senior Vice President, Capital Management and Investor Relations. Please go ahead, Ms. Brady.

Thank you, and good morning, everyone. Welcome to Sun Life's earnings call for the second quarter of 2025. Our earnings release and the slides for today's call are available on the Investor Relations section of our website at sunlife.com. We will begin today's call with opening remarks from Kevin Strain, President and Chief Executive Officer. Following Kevin, Tim Deacon, Executive Vice President and Chief Financial Officer, will present the financial results for the quarter. After the prepared remarks, we will move to the question-and-answer portion of the call. Other members of management are also available to answer your questions this morning. Turning to Slide 2, I draw your attention to the cautionary language regarding the use of forward-looking statements and non-IFRS financial measures, which form part of today's remarks. As noted in the slides, forward-looking statements may be rendered inaccurate by subsequent events. And with that, I'll now turn things over to Kevin.

Well, thanks, Natalie, and good morning to everybody on the call this morning. Turning to Slide 4. Our results this quarter once again highlight the strength and resilience of our balanced and diversified business model. Our underlying EPS was $1.79, up 4% year-over-year. Underlying net income was strong at just over $1 billion. Underlying ROE was 17.6%. These results were solid across all of our businesses with Asia, Canada, and SLC Management having strong quarters. The U.S. Employee Benefits business hit record earnings this quarter, and our stop-loss business in the U.S. performed well at a time when the industry is seeing challenges. This reflects our leadership position in the stop-loss market. We continue to take a long-term view on our U.S. Dental business, which has recently been affected by impacts to the U.S. healthcare environment. Tim will go through this in more detail. MFS continues to have solid earnings. While we experienced outflows this quarter, we continue to see strong signals of clients' confidence and interest in our offerings, evidenced by our strong total gross sales. Reported earnings were up over last year. The difference between underlying and reported earnings was primarily driven by real estate and market-related impacts. These impacts were timing-based, not structural and are expected to be neutral over the medium term. There was also a write-down of an intangible asset related to the U.S. Dental contract. Our capital position continues to remain strong, reflecting our focus on financial discipline and capital-light businesses. Our LICAT ratio at SLF was 151%, and we bought back close to $400 million of Sun Life shares through our share buyback program this quarter. Turning to Slide 5. We highlight our progress against our strategic imperatives, asset management, Asia, health, digital and people. We saw good momentum and resilience across our asset management and wealth platforms this quarter. At SLC Management, our performance continues to track well for the year. We had a strong quarter for capital raising with $6 billion of assets being raised, doubling over last year. Some notable highlights include the continued strength in Crescent U.S. Direct Lending and Crescent Solutions funds. MFS continues to experience outflows this quarter, reflecting the volatility in equity markets. Despite this, we're encouraged by MFS' total gross sales, which are up year-over-year and demonstrate client commitment to MFS. Our active ETF business continues to build momentum, and our fixed income business saw good net inflows this quarter at MFS. This quarter, MFS was named Best New ETF Issuer at the 2025 ETF.com Awards. MFS continues to play a strategic role in Sun Life's overall financial strength, delivering solid margins and cash flow to the organization. We continue to manage this business with a focus to achieve strong performance over the long term. In Canada, our Asset Management and Wealth businesses, driven by GRS, saw continued strength with assets exceeding $200 billion this quarter. In Asia, our Asset Management and Wealth businesses delivered a record quarter. In our India Asset Management joint venture, strong inflows to newly launched equity funds contributed to a nearly doubling of net wealth sales this quarter, while favorable markets helped drive wealth assets up 21% year-over-year. Individual Protection also contributed significantly to Asia this quarter with sales up 22% year-over-year. Our bancassurance distribution is delivering good results overall with sales up 14% year-over-year. We are pleased with the sustained growth in Asia CSM, which was up 23% since last year, ending the quarter at $6.2 billion. In Hong Kong, our diversified channel strategy continues to yield strong results. We achieved protection sales growth of 35%, supported by robust performance across our agency, bancassurance, and broker channels. We also launched an index universal life insurance product for professional investors, becoming the first insurer in the market to bring this innovative solution to clients. This product addresses the growing market demand for high-end wealth management solutions and shows our ongoing dedication to supporting our clients' evolving needs. Shortly after the close of the quarter, we announced a further investment in Bowtie. We've been on the ground with Bowtie since the beginning of their journey, and it's incredible to see their growth. They were recently recognized as the fastest-growing company in Hong Kong by the Financial Times in the rankings of high-growth companies in the Asia Pacific. We're excited to continue our partnership with them and to advance our shared goals of making health insurance simple, accessible, and affordable for clients. In Canada, we saw a strong sales performance for Sun Life Health, up 41% year-over-year, primarily driven by large case wins. In the U.S., our Employee Benefits business achieved record earnings and margins this quarter. In stop-loss, our industry-leading capabilities, expertise, and scale have served us well in this competitive market, and stop-loss continues to be a foundational part of our U.S. business and strategy. We made substantial progress this quarter in advancing our digital leadership, including the deployment of new generative AI capabilities, making it easier for clients and advisers to do business with us as well as helping us enhance our productivity and our operations. In Canada, we're excited about the launch of our reimagined mobile application. This new app features an enhanced health, wealth, and protection experience, facilitating easier access to health services and simplifying key tasks. We also launched Adviser Notes Assistant in Canada, a generative AI tool designed to enhance client experience and streamline workflows. In Malaysia, we enhanced operations with real-time underwriting capabilities to speed up the sales cycle. And in Hong Kong, we piloted Adviser Buddy, an AI chatbot to support advisers across the entire sales journey. In the U.S., we implemented straight-through processing for our supplemental health accident insurance to improve productivity and client experience. These are just a few examples of the work we are doing to drive digital leadership across our businesses. Sun Life people and culture remain central to our success. This quarter, we were named one of the best workplaces in financial services and insurance in Canada as well as one of the best workplaces for health and well-being in Ireland. Before I pass the call over to Tim, I want to acknowledge some leadership changes. Last night, we announced that Dan Fishbein, President of Sun Life U.S., plans to retire in March 2026. Over the past 11 years, under Dan's leadership, our U.S. business has transformed into a leader in health-related benefits and services, connecting the broader healthcare ecosystem and helping people access the care and coverage they need. Dan brought Sun Life further into the health space with services like care navigation, digital health programs, and clinical innovation interventions that complement core health coverage. I've been a teammate of Dan's on the executive team since he joined in 2014. I've been impressed by the impact he has had and how he has helped Sun Life evolve into a leader in the group benefit space in the U.S. He has truly made a difference. And I want to congratulate David Healy. David will become President of Sun Life U.S. on September 1, at the time which Dan will assume the role of Executive Chair of Sun Life U.S. until his retirement to ensure a smooth leadership transition. David is a seasoned executive at Sun Life with over 20 years of experience and is currently the President of Sun Life U.S. Dental business. Throughout his tenure, he has led and grown the Employee Benefits business, headed operations and technology teams, and managed the integration of key acquisitions, including Assurant Employee Benefits and Maxwell Health. His experience and leadership have contributed significantly to Sun Life's growth and success in the U.S. market. David's combination of technology and operations experience and his employee benefits background are perfectly aligned to our ambitions for the U.S. business. You will get to meet David and know him more in the coming months. I also want to recognize Kevin Morrissey, our Chief Actuary, whose voice has been a familiar presence on these earnings calls for nearly a decade. This will be Kevin's last earnings call as he prepares to retire this fall after an impactful 37-year career with Sun Life. Kevin and I have worked closely together throughout my entire 28 years at Sun Life, and I personally have watched him develop into a strong leader for us. His remarkable journey with Sun Life's companies has left an indelible mark on our organization, and he has helped train and develop many of our actuaries and has been an important voice in the industry. I'd also like to take this opportunity to welcome our incoming Chief Actuary, Brennan Kennedy. Brennan is currently our Senior Vice President of Global Asset Liability Management and brings over 25 years of experience with Sun Life to this new role. Both Kevin Morrissey and I have worked closely with Brennan over his entire career at Sun Life, and we are really pleased to see him take this next step. His deep expertise spans actuarial risk management, finance, and, of course, ALM. Brennan will be a valuable addition to our global leadership team. I want to congratulate both David and Brennan on joining the global leadership team. Dan and Kevin, on behalf of all Sun Life employees, thank you for your leadership and all of your many contributions over the years. We wish you both the very best in the future as you begin the next well-deserved phases of your lives. And with that, I'll turn the call over to Tim, who will walk us through the second quarter financial results in more detail.

Thank you, Kevin. Good morning, everyone. Turning to Slide 7. Overall, we are pleased with our second quarter 2025 results, which demonstrated the resilience of our business in the current environment. We reported underlying net income of $1.015 billion, up 2% year-over-year, while underlying earnings per share of $1.79 was up 4% over the same period. Asset Management and Wealth underlying earnings were flat compared to the prior year on higher fee income at SLC Management in Asia, offset by lower fee income at MFS and lower investment spread income in Canada. Group Health and Protection underlying earnings were up 7% year-over-year from higher U.S. Dental results and favorable mortality experience in Canada. Individual Protection underlying net income was down 10% over the prior year from unfavorable mortality experience in Canada and the U.S. Underlying return on equity was 17.6%, down from the prior year from higher average equity from earnings growth and changes to other comprehensive income from foreign exchange and interest rates. Reported net income for the quarter was $716 million. The variance between reported and underlying net income was driven by market-related impacts and an impairment charge on a customer relationship intangible related to the early termination of a U.S. group Dental contract. Market-related impacts reflected unfavorable interest rate impacts and real estate experience. Interest expense includes the impact of risk-free rates, swap and credit spreads, and other timing-related items arising from the market volatility experienced during the quarter. Real estate returns were flat for the quarter, below our long-term expected returns. Total contractual service margin, or CSM, which reflects future profits, increased 9% year-over-year to $13.7 billion, driven by strong organic CSM growth. New business CSM of $435 million was flat compared to the prior year. Organic capital generation, net of dividends, was strong at $673 million, above our target range of 30% to 40% of underlying net income. Our balance sheet and capital positions remain robust with an SLF LICAT ratio of 151%, up 2 points from the prior quarter as organic capital generation more than offset the impact of dividends, share buybacks, and markets. Holdco cash remains solid at $1.1 billion after returning almost $1 billion to shareholders during the quarter, and our leverage ratio remains low at 20.4%. Finally, book value per share increased 5% over the prior year, demonstrating our ability to generate strong growth while returning value to our shareholders with 4.8 million shares repurchased this quarter under our share buyback program. Turning to our business group performance on Slide 9. MFS' underlying net income of $184 million was down 5% year-over-year, primarily reflecting lower fee income from lower average net assets. Pretax operating net margin of 35.1% decreased by 1.4 percentage points from the prior year on lower fee income from a decline in average net assets and interest income. Assets under management of $635 billion were up 3% over the prior year and up 5% over the prior quarter. The sequential movement in AUM was driven by market appreciation, particularly in the latter half of the quarter, partially offset by net outflows. Outflows of $14.3 billion included retail outflows of $5.9 billion and institutional outflows of $8.4 billion. Retail outflows continued from market uncertainty, and institutional outflows reflected primarily client rebalancing activity. Overall long-term investment performance for MFS remains strong with 90% of fund assets ranked in the top half of their respective Morningstar categories for 10-year performance. Fixed income performance was also strong with 98% of fund assets ranked in the top half of Morningstar on a 10-year basis. Turning to Slide 10. SLC Management generated underlying net income of $45 million, up 7% year-over-year, but down from a record result last quarter. The sequential decline is attributable to catch-up fees and seed investment gains recorded in the prior quarter. This quarter's results included a modest seed investment loss, which contributed to the below-trend result. Fee-related earnings of $89 million were up 37% year-over-year, driven by strong capital raising and lower expenses. Reported net income was $0 this quarter, driven by acquisition expenses and market-related impacts. SLC Management continues to demonstrate strength across the platform with capital raising of $6 billion this quarter, reflecting strong activity in SLC Fixed Income, Crescent, and BGO. Deployments remained strong also at $6 billion for the quarter, reflecting continued attractive investment opportunities for private assets. SLC's fee-earning AUM of $194 billion was up 9% year-over-year, driven by deployments and market appreciation. Sequentially, fee-earning AUM was down 4%, driven mostly by currency impacts. Turning to Slide 11. Canada's underlying net income of $379 million was down 6% year-over-year as strong business growth was more than offset by lower investment results and less favorable insurance experience. Reported net income of $330 million was up 13% year-over-year on more favorable market-related impacts. Asset Management and Wealth underlying earnings were down 4% year-over-year from lower investment spread income driven by lower yields on investment contracts. Wealth AUM of $203 billion was up 12% year-over-year on market appreciation and net inflows. Group Health and Protection underlying earnings were up 1% year-over-year, reflecting more favorable mortality experience and business growth, partially offset by less favorable morbidity experience due to higher-cost disability claims in the quarter. Group sales were up 41% year-over-year, driven by large case sales. Individual Protection earnings were down 16% year-over-year due to unfavorable mortality experience, which mostly offset a corresponding gain in the CSM. Individual Protection sales were down 19% year-over-year, driven by third-party sales. Turning to Slide 12. Sun Life U.S. underlying net income was $143 million, down 4% from the prior year. In Group Health and Protection, underlying earnings were higher by 10% year-over-year, driven by business growth in Employee Benefits and Dental, partially offset by unfavorable experience. U.S. Group Health and Protection sales of $226 million were down 7% year-over-year, reflecting the impact of pricing discipline in a competitive market for medical stop-loss, partially offset by higher government and commercial Dental sales. In medical stop-loss, results this quarter were in line with recent expectations. Morbidity results reflected the expected reserve accumulation on January 1, 2025, business, including the previously indicated 2% pricing shortfall. In Dental, this quarter's results reflected higher Medicaid claims from higher per-member utilization and severity. In addition, the uncertainty around Medicaid funding in the U.S. has slowed repricing actions with both states and health insurers and is contributing to elevated Dental loss ratios in the near term. As a result, we no longer expect the business to achieve $100 million in earnings this year. Given the near-term challenges, we are reforecasting our expected earnings trajectory for the business. We are confident in the long-term outlook for Dental and remain committed to the 12% plus medium-term underlying earnings growth objective we set out for the overall U.S. business segment. Going forward, we expect Dental to contribute at least 1/3 of the overall U.S. earnings growth. Individual Protection underlying earnings were down 46% year-over-year, driven by unfavorable mortality experience and credit impairments. Reported net income of $74 million was down 19% year-over-year and included an impairment charge, which more than offset improved market experience. Turning to Slide 13. Asia posted a record underlying net income of $206 million, up 13% year-over-year. Individual Protection earnings were up 7% year-over-year on business growth and higher investment contributions, partially offset by higher expenses from investments in the business. Asset Management and Wealth earnings grew 67% over the prior year on higher fee income from strong AUM growth. Reported net income of $98 million was lower year-over-year from unfavorable market-related impacts. We continue to see strong sales in Individual Protection, up 22% year-over-year, driven primarily by momentum in Hong Kong across all channels, solid contributions from our bancassurance deal in Indonesia, and sales growth in India. Asia's total CSM of $6.2 billion grew 23% year-over-year, driven by strong organic CSM growth. New business CSM of $299 million was up 34% from strong sales and margins in Hong Kong. We're pleased with the overall results we've delivered this quarter despite the challenges in the macroeconomic and geopolitical environment. We remain confident that our strong fundamentals, diversified business mix and geographies, and robust capital levels will continue to support our ability to achieve our medium-term objectives and deliver on our purpose. In closing, my executive team colleagues and I would like to extend our congratulations to Kevin Strain, who has been named the 2025 International Business Leader of the Year by the Canadian Chamber of Commerce. This award celebrates Kevin's leadership and strategic pursuit of global opportunities, which have significantly elevated Canada's international presence. On behalf of all Sun Life's employees, Kevin, congratulations on this outstanding achievement. With that, I will pass it back to Natalie for the questions and answers.

Thank you, Tim. To help ensure that all participants have an opportunity to ask questions this morning, please limit yourselves to 1 or 2 questions and then requeue with any additional questions. I will now ask the operator to poll the participants.

Our first question is from Doug Young with Desjardins Capital Markets.

Just maybe starting out on the U.S. group and the Dental side. You no longer think you can hit $100 million of earnings in 2025. I don't think that will be a shock to most people. But you also put out a target of $250 million by 2029, with no mention of that. Just wondering how we should think of the evolution of the U.S. Dental business over, call it, the next 5 years? And if you can weave in, I think you said you think 1/3 of U.S. earnings growth is going to come from the Dental business. Maybe if you can kind of wrap that all together. And then there's obviously a lot of goodwill and intangibles related to the business. You spent $3.1 billion on it. And the questions I'm getting is that does that need to get written off? At what point in time do you look at that as a potential write-off? And can you talk about the size of the goodwill and the intangibles related to DentaQuest?

Doug, this is Tim. Maybe I'll kick this off. So in light of the near-term uncertainties that I referenced in my opening remarks, particularly around Medicaid and the repricing, we're having to reforecast our earnings outlook for the business. And rather than provide a single point estimate on earnings numbers for a number of years out, I would really refer you back to our medium-term earnings growth objective for the U.S. segment overall. As I said, we're committed to the 12% plus objective that we shared at Investor Day. And as mentioned, expect that Dental will be at least 1/3 of that overall earnings growth for the segment. And then looking ahead, we're confident in the long-term outlook for the business. We're the largest Dental benefits provider in the U.S. by membership and have a strong brand presence in the market. And we see a lot of growth opportunities in the commercial space, which has higher margins, the opportunity for synergies with our employee benefits business, the opportunities we have to reduce expenses and invest in the business to make it more efficient. And then ultimately, the repricing actions to get back to the pricing target levels over time is really what's giving us confidence in the business in the long term. And then on your second part of the question related to intangibles. At the time of the acquisition, we set up customer relationships and system intangibles of about $1.2 billion, and we had goodwill on the books of about $2 billion. And when I look ahead for the business, the customer relationship intangibles, those are tied to specific contracts. And so in the case of this quarter, there was one contract that terminated early. But overall, because of the outlook that I referenced over the long term, we still remain confident in our goodwill. We test that for impairment regularly. We have ample cushion of fair value above that at this point. So nothing further to indicate at this time.

Could you provide some insights on why the ASO group Dental contract was terminated? Additionally, it seems the repricing process is progressing slowly. What observations do you have regarding that situation?

Yes, it's Dan Fishbein. Regarding both items, the client that terminated was part of a commercial ASO arrangement related to the seller. We had set up a separate intangible for that contract for that reason. There is a natural cycle in existing business, with some clients leaving and new ones coming in. Without going into specifics about this particular client, our assessment is that they are a nonprofit client who prefers to work in the future with another related party from their nonprofit sector, and they may not have felt entirely comfortable with a public company. Overall, the relationship has been positive, and they will remain with us until August 2026. We are currently collaborating with them on the transition. This situation is quite unique, and we do not believe it reflects broader issues. Now, remind me of your second question.

Repricing.

Thank you for your question. The reconciliation bill that was recently signed into law has created challenges in negotiating appropriate pricing with states and health plans. However, we believe the long-term impact on our business will be minimal, as 80% of our Medicaid membership consists of children, and the bill primarily influences adult coverage. Nevertheless, the uncertainty surrounding future Medicaid funding has led to a slowdown in states and health plans adjusting rates to where they should be, especially after the changes that occurred following the end of the public health emergency. We are still making progress on pricing, but it will take longer than we initially expected.

Doug, it's Kevin. I wanted to emphasize a few points about the Dental business, which is a significant aspect of the U.S. group sector. It's a repriceable area that requires little capital investment. With the acquisition of DentaQuest, we entered the Dental market, adding scale and new capabilities. Previously, we had no presence in the Medicare and Medicaid sectors, which are crucial to the U.S. healthcare system. This sector is currently facing various challenges similar to those our competitors are experiencing, including increased usage by both members and providers when there's concern about benefits being reduced. This trend is partly due to a public health emergency and the funding issues discussed by Dan. States are taking a cautious approach to pricing changes amidst funding uncertainties. However, we see the potential for long-term growth, as Tim pointed out, in expanding our commercial presence and optimizing our Medicare and Medicaid services. Dental remains a vital component of group benefits, and while this is a challenging time for all in the sector, we're committed to navigating through it and are taking the right steps to do so. Keeping this perspective is important.

No, I do appreciate that. And just one follow-up, Manjit. EMPF, I know you're a big player, Manulife, obviously kind of quantifies what the impact that has on underlying earnings. Can you quantify what the impact is for your MPF business?

Yes, you're correct. As mentioned yesterday, the Monetary Provident Fund Scheme Authority will assume the administrative responsibilities for the MPF assets. Consequently, we will no longer earn the fee for administering those assets, which will impact us by approximately CAD 10 million each quarter. Overall, this has been a strong business for us, with good growth over the years. It generates a solid return on equity, and we anticipate that trend will continue.

I want to mention that we are shifting our focus to increase our asset management efforts in that area, and Manjit and the team have been working on this. This will be a significant aspect of the EMPF business model moving forward.

I want to ask a question about the U.S. medical stop-loss business. I'm looking at the Group Benefits underlying earnings of $121 million for the quarter compared to $124 million a year ago in the same quarter. I want to understand what proportion of that might be attributed to stop-loss versus employee plans and whether there is a need to accelerate repricing actions in stop-loss due to claims loss trends across the industry.

Thanks. We were actually pleased with the stop-loss results in the second quarter. As you may recall, in the fourth quarter, we and everyone else saw a significant spike in medical expenses in our stop-loss business. We entered this year with some concern about where that would go. However, the experience has largely stabilized and has aligned with the expectations we set at that time. Our earnings for stop-loss in the quarter are not broken down between stop-loss and employee benefits. It was slightly down compared to last year, but very much in line with the expectations we laid out. We have also seen some improvement in the loss ratio for the January 1, 2024 cohort, which is now almost entirely complete. While it is not back to where it was before the fourth quarter, there has been improvement since then, which is quite reassuring. We are also starting to get some experience on the January 1, 2025 cohort, but we are still very early in that process with only about 12% of the claims in. What we have seen so far is similarly reassuring. As we mentioned at that time, we thought our pricing for 2025 was about 2% less than it probably needed to be. We have certainly implemented those price increases, mainly during the first quarter, and we have been able to achieve those increases. Therefore, we feel that the business moving forward is appropriately priced to reflect the experience that we are observing.

Okay. That's a good update. Second question then would be with respect to SLC. So there's a fairly big difference between the year-over-year growth in earnings up 37% and then the underlying up 7%. And I get there's some accounting differences and don't need an explanation for that viewpoint. But just more like which one do you think is more of an indication of true run rate earnings growth in that business? Or maybe the answer is somewhere in between, but just trying to get a better understanding of what really is indicative of how this business is growing from an earnings perspective.

Yes. Thanks. It's Steve. I think it's important to look at our core business, which is quite stable and will align with assets under management over time. Management fees, fundamental management fees, distribution fees, and property management fees will closely follow AUM. A variable part of management fees is catch-up fees, which can fluctuate significantly from quarter to quarter since they depend on when funds close. Certain fund closures can lead to catch-up fees; these are never negative, only positive, but are quite irregular. Fee-related earnings are the best indicator of the business's core earnings potential, as they exclude any marks on seed investments. Although fee-related earnings are influenced by quarterly variations like catch-up fees, they remain relatively stable and will correlate with AUM. Below that, you'll see some fluctuations in underlying net income due to marks on seed assets. We experienced some noise this quarter that should likely reverse regarding our strong industrial portfolio that is considered for sale in the wealth channel. This affects underlying net income but is below the fee-related earnings line. I suggest monitoring management fees and fee-related earnings alongside our fundraising performance and net flows, which are clearly on an upward trajectory. Our fundraising for the quarter reached $6 billion, doubling from last year and increasing from $4.4 billion last quarter, with positive net flows of approximately $4 billion to $5 billion this quarter.

Paul, it's Kevin. I'm just going to add, we're on track to achieve the $235 million that we gave at Investor Day. So if you're looking at the next 2 quarters, that $235 million gives you a sense that what we're expecting. As Steve mentioned, we had higher seed gains and catch-up fees in the first quarter. And the catch-up fees this quarter were actually 0 and the seed investment was a loss. And so you're seeing a little bit of volatility, but I would think of it as targeting the $235 million. And then on our Investor Day, we gave you numbers around 20% growth in underlying earnings and 20% FRE growth over the medium term. And that's the way to think about that. We feel like we're on track on SLC, and we're seeing flows that are consistent with that. And the big piece we needed to do, and we talked about this last quarter, was getting ready for the buy-ups and the leadership team, and we've made some really significant announcements there, which we think are really positive under Steve's leadership.

If I could just inject one other quick comment. The underlying net income this quarter of $45 million, I would say, was below the run rate that I've mentioned, but marginally below. It was a fairly normal quarter. We had kind of 2 negatives. One was a markdown on our portfolio, which I think was kind of noise. And the other was that we had 0 catch-up fees this quarter. Usually, we have some, and that was partially offset by some adjustments to some expenses. And so I would say that impacted us. The net impact of that on UNI was probably, I don't know, mid- to high single digits versus what I would consider our normal run rate at this point.

Okay. I'll respect the 2-question limit and let someone else fire away.

Manjit, in terms of the growth that you've been experiencing in Asia, obviously quite positive. But moving forward, as we're expecting to continue to grow the business, do you think that margins are defensible? And what are you seeing as a competitive response?

John, it's Manjit. Obviously, as you know, we're in 8 different markets. There's different dynamics in different markets. But overall, we feel good about the growth that we've seen over the last little while. We feel we're in the right markets. We're making investments into our business. We're focusing on the client, and we're doubling down on execution. And I expect that to continue and for the foreseeable future to kind of continue to deliver good results.

And Manjit, could you provide more details regarding the investment in Bowtie? What advantages does it offer to Sun Life, and what value does Sun Life provide to Bowtie beyond financial support?

As Kevin mentioned, we've been in partnership with Bowtie for quite a number of years. They are a digital company that helps with insurance for our clients in Hong Kong. And they're a direct-to-consumer model that complements our distribution force. So I think it's a good partnership has been, and we expect that to continue.

Just the driver of that severity and frequency trend, I think Kevin touched upon one factor there. People are worried about losing their coverage. I guess, is there more of that to come because it sounds like it, but could get worse even because Q3 is the seasonal uptick in Dental claims, back-to-school stuff. And then beyond that, I'm just trying to get a sense of what the pipeline for these claim activities looks like.

Yes. Thanks. You're absolutely right that the third quarter is the most adverse in terms of seasonality. We fully expect that. So that's something to look ahead to. And of course, that's because we mostly cover kids; and back-to-school toward the end of the summer, parents take their kids to the dentist. So the third quarter usually has the least favorable experience of the year. Conversely, the fourth quarter has the best. During the holidays, etc., there's less utilization. So we would expect that pattern this year to see some challenge in the third quarter and then very good results comparatively in the fourth quarter. In terms of what's driving the increase in utilization and severity, first, in the second quarter for us, there were some unique aspects there in that we did have some claim backlog that we were working down. We also had one plan that asked us to go back and reprocess some claims that they had submitted incorrectly up to a year ago. So there is some one-time effect in our experience. Some of that led to some increased severity, and we would not expect that to recur. But as far as the longer-term trend, we are seeing, and of course, all of the health insurers are seeing as well. It's not just in Dental, a meaningful increase in severity as well as in some in utilization. We do think that billing practices by providers aided by AI is driving some of the change in severity. So we're certainly both upping our game on how we handle that, but also we're going to need to make sure that, that's fully reflected in pricing going forward because that does seem to be a dynamic that's happening across segments and across the entire landscape.

Okay, great. Regarding the pricing issue, it's often considered a way to tackle margin challenges. What is the current situation compared to normal timings? Additionally, what is your pricing power? If you needed to increase prices by 5%, can the state just say no and make you absorb it? I'm curious about how that works.

Sure. Let me go through that a little bit and particularly with the focus on Medicaid, which I think is your question. In Medicaid, the rates are reset annually. So that's good. That's a very good aspect of this. But they are reset by the state Medicaid authorities, either directly to us in where we have those direct relationships or through health plans where we're subcontracting with those health plans. So we can have influence over the rate, and we've dramatically increased our actuarial staff and our capabilities in that area over the past couple of years. And we provide a lot of data insight and opinion to the states, which they do take into account. But to your point, ultimately, they set the rate. Now they are required under the law to set actuarially sound rates, which typically means they look at the last 3 years of experience and then set the rate based on that experience plus whatever trend in Dental expense they apply to that. Part of the challenge here, of course, has been that in the wake of the public health emergency ending, the business mix shifted rather suddenly and is not completely yet reflected in the past 3 years of experience that emerges over a 3-year time frame. Obviously, all our work with the states has been to get them to accelerate recognition of that effect. And in some cases, that was effective and in some cases, that's been less effective. And now with the overhang of uncertainty about funding in Medicaid, that has certainly slowed that process down. We do believe that the rates will get to the right place once we get through that full 3-year cycle. That's what the law requires and certainly has been the history, but it is taking longer than we had originally hoped for sure.

That was part of my question, like how much longer, what was your expectation, and now given these dynamics with the new expectation?

Yes, I can give you a little bit of perspective on that. Last year, we were able to achieve about $140 million in rate increases. We expect to achieve additional rate increases this year, but not as much as last year. And we anticipate that it likely will take through 2026 to get the rates back to full expected margins.

First one I had, I wanted to touch on stop-loss. I think it was mentioned in some of the remarks that there was a little bit of favorable development on 2024. I just wanted to see if you could size that for us only because small percentage changes on like full year '24 can have a pretty magnified impact on the current quarter. I just want to make sure I was understanding the impact of that correctly embedded in the segment reporting you guys gave.

Yes, Alex, there are multiple overlapping cohorts each quarter, which makes things quite complex. In this quarter, we experienced results from the 1/1/24 and non-1/1/24 cohorts, as well as some final results from 2023. These results don’t always align. I can share that we saw a significant spike in the 1/1/24 cohort in the fourth quarter, but during the first and second quarters, about one-third of that has reversed. Two-thirds of the adverse experience remains, but one-third has improved. The 1/1/25 cohort is also important; we have only received about 12% of claims so far, mostly a reserve pick. We're still assuming we were about 200 basis points off in pricing, which is reflected in our results. However, the initial 12% we have seen is consistent with or possibly slightly better than our assumptions. I hope this provides some clarity.

Yes. That is really helpful. Second one I had is on MFS. And just wanted to see if you could talk a little bit about what you see in the back half for flows. I mean it sounded like you're optimistic on the inflow piece of things. Do you have any visibility on the outflows and just what it all may mean going into the back half of the year?

This is Ted. It's always very difficult to predict flows on a quarter-to-quarter basis. We think the trends that have been in place are likely to remain in place until they're not. So we've got institutional rebalancing from equity to fixed income, where our current balance leads to outflows there. We also have the retail market at an elevated redemption rate, which again, we would not expect to be sustainable for the long term, but see no near-term abatement. So I think we wouldn't predict the back half of the year, but the trends in the near term will probably stay in place, and long-term, we remain optimistic about returning to net flows in the future.

I have a couple of questions regarding the U.S. Dan, regarding your comments on Dental, I would like to know if you expect to reduce Medicaid Dental for a period while increasing commercial during this transition. Or, do you anticipate that the Medicaid business will continue to grow through this transition? It appears that this issue is really about a one-year period lasting until the end of 2026, not extending beyond that. That's my first question.

The Medicaid business has indeed seen a decline since the public health emergency ended, losing 19.5% of our membership which accounted for approximately $400 million in premium and fees. However, our overall Dental business has actually grown by $200 million since acquiring DentaQuest. We are actively making many sales, and despite the previous membership losses, we are expecting considerable new business in the coming years. From June 1 of this year until January 1, 2026, we anticipate adding 6 million new members, primarily in Medicaid, but also including some Medicare Advantage and commercial business that are in different stages of integration. Our sales pipeline remains strong. Additionally, Medicare, Medicaid, and government programs now comprise over half of the U.S. healthcare market, making it essential for us to be involved in this area. We are committed to growing within this space as the market leader, and we foresee continued growth at a healthy pace in the short and long term.

Tom, it's Kevin. I want to add that while you mentioned the commercial side, that's not where our main focus is. Dan and I have discussed this frequently. David, who is leading Dental, and I have been examining the commercial space and considering how to utilize the capabilities we've gained from DentaQuest. We were previously very small in the commercial area, and there is significant potential for us to enhance our presence there over the medium term. We view this as an opportunity to strengthen our business. It's also crucial for us to have a balanced mix of business in the U.S. While having Medicare and Medicaid is vital, expanding our commercial segment is strategically important to us as well.

And I think it's worth noting that the commercial has grown at a significantly faster pace over the past 3 years than even the Medicare and the Medicaid. And we would expect that faster pace to continue. Commercial right now represents less than 20% of the total business mix. We'd like to see that be a significantly higher proportion in the future, and that's what we expect.

My quick follow-up is, Dan, you mentioned that there was also some one-timer-ish type charges in the quarter. In Dental, can you quantify that relative to the breakeven earnings in the quarter, what would it have been if we stripped out that charge?

Yes. To provide some perspective, especially comparing the first quarter to the second quarter, these two numbers show a significant difference. In the first quarter, we received a retroactive premium payment from one of our largest state partners, which was in the high single digits. We also benefited from some nonrecurring positive investment income. In this quarter, a client requested that we reprocess claims they had submitted incorrectly from about a year ago. When you consider these three factors, they account for the entire difference between the first and second quarters. If we split the results of the first two quarters in half, that would give a clearer picture of what the outcomes would have looked like across those two quarters.

When examining the Dental segment, which generated only $2 million in the quarter, it still outperformed expectations. This appears to be partly due to improved other fee income and more effective expense management. I would like to explore these two aspects further. The other fee income increased by over $20 million year-over-year, exceeding expectations across different regions including Asia, Canada, and the U.S. Could you provide more details about what comprises this other fee income? Additionally, could you discuss elements related to Sun Life Health, ASO fees, or other components? I am also interested in your thoughts on the outlook for this better-than-expected figure. I have a follow-up question as well.

Tom, it's Tim. I'll kick that off and if Dan wants to supplement on the U.S. You're right. The other fee income line includes a number of items. So we have our health group businesses in Canada and the U.S. That's our administrative services-only businesses. That's what earns fees. It also includes our wealth businesses across Canada and Asia. And so we had a very favorable quarter this quarter was up year-on-year, about $18 million in total, up quarter-over-quarter, about $22 million. And a large part of that was the growth in Asset and Wealth Management that we saw, in particular, in Asia as well as in Canada. And so those businesses have performed very well with higher markets, and that's driving the bulk of the change. In the U.S., it does include care delivery services that we provide. Those are fee income services that was up moderately in the quarter as well. I wouldn't expect that necessarily that trend line to repeat, but it was favorable for this particular quarter. And then in Canada, we have our CDCP program, our Dialogue business, etc., and that's performing very well. So that's where you're seeing the growth in the fee income.

Should we be thinking about this as a run rate here? Or sorry, I'll let you go again. And then maybe the 2, you can let me know if you think this is more of a run rate what we see in this quarter for this line.

It's elevated. There were a couple of onetimes that I alluded to. But as long as funds continue to perform in the wealth businesses, you'd expect continued growth in that line item.

I wanted to make an additional but related point regarding your question about the results, which were fairly close to the first quarter despite the Dental outcomes. The most significant positive aspect to note was the outstanding performance from our Employee Benefits business. This segment, which includes group life, disability, and voluntary products, achieved its best results ever, driven by both growth and margin improvements.

Tom, it's Tim again. So as you're right, we did have favorable results in our other expenses. The numbers you referenced, quarter-over-quarter and year-over-year, are correct. Most of that is coming from our corporate segment. And you can see the favorable result we had there. This is driven mostly by timing of initiative spend that we have and as well as incentive compensation, as you highlighted. We do expect that initiative spend will ramp up a bit in the second half of the year. So we will give back some of this favorability, but we haven't revised our overall expectation of roughly $100 million a quarter for the corporate segment, so you can use that as a better indicator. We are seeing great traction from our overall expense efficiency program. We had $25 million of savings in the quarter. We're still well on track for the $200 million in total cost efficiencies by the end of 2026. We have delivered about 66% of that to date. So we are taking action and have been very disciplined on expenses, but there was some timing of favorability in that, particularly in the corporate segment.

In the corporate segment, it was $110 million. And are you saying that it should be $100 million going forward per quarter? So it was actually a little bit higher.

Yes. We get some volatility in that line. As I said, there's a number of things that go through that. We have the incentive comp, as I referenced earlier. We also had lower interest income on debt. We had a repayment of the loan that we had that was financing the bancassurance agreement we had in Indonesia. So I think the $100 million is a more realistic number. We haven't tipped over that actually in recent quarters. And so that's generally the range that we expect to be in going forward.

I want to just turn back to the Dental business here and a comment that was made earlier. So just to be clear, you have $1.2 billion of these customer-related intangibles on the balance sheet in this quarter, a $61 million write-off was one client. So presumably, if other clients continue to leave Sun Life here that are attached to these intangibles, there could be further write-downs of these intangibles. Is that correct?

Go ahead, Tim.

I was just going to say the intangible that we had for this quarter related to a very specific customer. So that was set up as a stand-alone contract. It was unique for the reasons that Dan mentioned earlier. It was with the seller. So that's pretty unique, and just given the size of that contract. All the other contracts are bundled together, and we look at that in aggregate as part of the administrative services clients or in the case of the risk-type clients. So those are aggregated. So we can expect some volatility in customer relationships, but there's also a growth opportunity there. So we're comfortable with the carrying values that we have on those intangibles.

Okay. Okay. And then just moving on to MFS. And then the question is on margins. I wonder if you could talk about the outlook for margins on this business. I know there's seasonality here; it's quite well understood. So I'm talking about the 1.4% year-over-year drop in margins here. It's a bit steeper than I had expected. And if I have it right, there's been year-over-year drops in 3 of the past 4 quarters. So I'm just wondering, is there an emerging trend here where margins are starting to move structurally lower at MFS? Or am I just kind of reading too much into it?

Sure. This is Tim. I'll start and see if Ted wants to supplement. So the decline year-on-year that we saw in margin was really driven by lower average net assets. We had average net assets last year in the second quarter of $620 billion. And for Q2 this year, it was $608 billion. Now we saw a large spike in the AUM at the end of the quarter. The funds really rallied, but it was lower during the period given all the market uncertainty. So that is the single biggest driver to the margin change is the average net asset. And so the 140 basis points that you referenced year-over-year is driven by that. The other dynamic is MFS earns interest income on cash and short-term balances; and not dissimilar to Sun Life overall, those balances have come down. In the case of MFS, it's because some of those short-term investments have been used to seed funds like the ETF launches and other products. So those balances are down, and that coupled with lower short-term rates has declined that. But the biggest driver is going to be that average net assets. And as you said, there is seasonality. So in the first 2 quarters, we have incentive comp that goes through. That's when the awards mature. And then in the third and fourth quarters, we typically get much stronger results. So you'll see that margin improvement. When you look back, it was hit 40% in Q3 and Q4 in the past. And so as average net assets improve, you'll see that margin come back.

This is Ted. So just to be clear, to summarize, no change to how we think about margins structurally through a cycle and over time, as Tim just outlined. Nothing that Tim outlined talked about fundamental cost structure items. We manage costs extremely tightly through all points of the cycle so that at times when net assets are down, we've got the other items that Tim talked about; we don't need to think about cutting into things that will harm long-term results. So again, to wrap up, no change to long-term views on margins.

I have sort of a related question about MFS margins. Clearly, the flows as well as what happened intra-quarter, hurt the AUM. But one could sort of easily come up with a period where markets are not accommodating, markets are down 10%. That's certainly something we've all seen, and outflows remain at this level. The question is, what is your capacity to manage expenses down abruptly in a period where AUM is under pressure?

So the vast majority of our expenses are actually completely variable with assets. So passively, our expenses come down as assets and revenues come down. The remainder that is not completely variable, as I mentioned before, we manage pretty tightly, and we probably wouldn't pull those levers. So in a strong market correction downward, you would see some hit to margins, but very much buffered by the variable nature of our cost structure. Also, while we're not a bear market shop per se, it would be more likely than not that our performance relative to benchmarks would be strong in a down equity market environment, a sharp down equity market environment, which would obviously be a good setup for future flows.

Did you notice those types of inflows early in the quarter when the situation became challenging or during 2022 when the markets were weak? Did you observe a similar recovery in your net flows at that time?

You wouldn't see flows be that shortly following performance. So we did see the performance that would have led to, we believe, longer-term flow tailwind. But in an experience where the market is down sharply and we're outperforming, that doesn't translate to flows. And in fact, what it tends to translate to on the retail side, in particular, is redemptions broadly, not specific to MFS, but redemptions broadly as retail clients sell into weakness that perhaps they should be buying.

I have a couple of questions regarding the U.S. Dan, in your comments on Dental, could you clarify whether you anticipate a reduction in Medicaid Dental for a period while increasing commercial? Or do you expect to continue growing your Medicaid business during this transition? It appears to be an issue primarily confined to the year ending in 2026, not extending beyond that. That's my first question.

The Medicaid business has certainly contracted since the end of the public health emergency from early 2023 to mid-2024. When the public health emergency concluded, we saw a 19.5% drop in membership, translating to about $400 million in premium and fees. However, the overall Dental business has increased by $200 million since we acquired DentaQuest. We are actively making sales despite the past losses. Looking ahead, we have a significant amount of new business coming in. Between June 1 of this year and January 1, 2026, we anticipate adding 6 million new members, primarily in Medicaid but also in Medicare Advantage and some commercial sectors that are in various stages of implementation. Our sales pipeline remains strong. Furthermore, as Kevin mentioned earlier, Medicare, Medicaid, and government programs now comprise over half of the U.S. healthcare market, making it crucial for us to remain engaged in that sector. We are continuing to grow here and expect sustained growth not only in the long term but also during the upcoming 1 to 2 years.

Tom, this is Kevin. I want to add that while you started with the commercial side, that's not the area we are focusing on. Dan and I discuss it frequently, and David and I have been exploring the commercial space, particularly regarding how to leverage the capabilities we acquired with DentaQuest. Our presence in the commercial space was minimal, and we see substantial opportunities to strengthen that sector over the medium term. We believe it’s essential to align our business mix in the U.S. With Medicare and Medicaid being significant, as Dan mentioned, it's essential for us to also grow the commercial sector strategically.

And I think it's worth noting that the commercial has grown at a significantly faster pace over the past 3 years than even the Medicare and the Medicaid. And we would expect that faster pace to continue. Commercial right now represents less than 20% of the total business mix. We'd like to see that be a significantly higher proportion in the future, and that's what we expect. Yes. To provide some perspective, especially when comparing the first quarter to the second quarter, these two numbers show a significant contrast. In the first quarter, we received a retroactive premium payment from one of our largest state partners that was in the high single digits. Additionally, we experienced some one-time favorable investment income. In the current quarter, we had a situation where one client requested us to reprocess claims they had submitted incorrectly about a year ago. When you consider these three items, they explain the entire difference between the first and second quarters. Therefore, if you take the results from the first two quarters and average them, that would give a clearer picture of what the outcomes would have been in those two periods.

Looking at the Dental segment, which brought in only $2 million for the quarter, performance still surpassed expectations, partly due to improved other fee income and better expense management. I’d like to explore these two areas further. The other fee income rose by over $20 million year-over-year and exceeded expectations across Asia, Canada, and the U.S. Could you provide more details on what comprises that other fee income? It might be helpful to discuss elements like Sun Life Health, ASO fees, and similar contributions. Additionally, how should we interpret the outlook for this income that performed better than anticipated? I have a follow-up question as well.

Tom, it's Tim. I'll kick that off and if Dan wants to supplement on the U.S. You're right. The other fee income line includes a number of items. So we have our health group businesses in Canada and the U.S. That's our administrative services-only businesses. That's what earns fees. It also includes our wealth businesses across Canada and Asia. And so we had a very favorable quarter this quarter was up year-on-year, about $18 million in total, up quarter-over-quarter, about $22 million. And a large part of that was the growth in Asset and Wealth Management that we saw, in particular, in Asia as well as in Canada. And so those businesses have performed very well with higher markets, and that's driving the bulk of the change. In the U.S., it does include care delivery services that we provide. Those are fee income services that was up moderately in the quarter as well. I wouldn't expect that necessarily that trend line to repeat, but it was favorable for this particular quarter. And then in Canada, we have our CDCP program, our Dialogue business, etc., and that's performing very well. So that's where you're seeing the growth in the fee income.

This concludes today's call. A replay of the call will be available on the Investor Relations section of our website. Thank you and have a good day.

This brings to an end today's conference call. You may disconnect your lines. Thank you for participating, and have a pleasant day.